אבסטרל 400 מק"ג - Abstral 400 mcg
ש××× ×× !
×ת×ר××: 13/02/2025 (× ××ק ×××ר×× × 16/11/2025) ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 13/02/2025 (× ××ק ×××ר×× × 16/11/2025) ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N01AH Opioid anesthetics | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ×××××ת ×××ª× ×ת×ת ××ש××, TABLETS SUBLINGUAL ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain. | |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×ת××ת ××× ×× | Posology and method of administration | |||||
| ×ת××××ת × ×× | Contraindications | |||||
| ת×פע×ת ××××× | Undesirable effects | |||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | |||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | |||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | |||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | |||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| |||||
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××ס××¨× 400 ×ק"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | GRÃNENTHAL GMBH, GERMANY |
| ×©× ××¢× ×ר×ש×× | NEOPHARM LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 04/2014. ר×ש××× ×ת×ר××: 09/2017 |
| ת×ר×× ×¢×××× ××ר×× | 13/02/2025 (× ××ק ×××ר×× × 16/11/2025) |
ת××× ×ª ×ר×××